Business Wire

VERTEX-PHARMA

Share
Vertex and Republic of Ireland Expand Long-Term Cystic Fibrosis Medicines Reimbursement Agreement to Include Triple Combination Therapy for All Eligible Patients Ages 12 and Over Once Licensed

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today confirmed that, following recent collaborative discussions, it has negotiated an agreement with the Health Service Executive (HSE) in the Republic of Ireland to expand the existing long-term cystic fibrosis (CF) reimbursement agreement to include the triple combination regimen (elexacaftor, tezacaftor and ivacaftor), which is under review and pending approval by the European Medicines Agency, for all eligible patients ages 12 and older in line with the potential future licensed indication.

This expands the existing agreement which had already included access to current and future Vertex medicines for people in Ireland with CF of any age who:

  • Have one of the specified mutations as included in the KALYDECO® marketing authorization (G551D, G551S, S549R, G1244E, S1251N, G1349D, S1255P, G178R or S549N ) or
  • Are homozygous for the F508del mutation or
  • Are heterozygous for the F508del mutation and have a specified mutation (P67L , D579G, D1152H, R117C, 711+3A→G, 2789+5G→A, L206W, S945L, 3272-26A→G, R352Q, S977F, 3849+10kbC→T, A455E or R1070W ) and people ages 18 and older and have an R117H mutation.

This innovative long-term agreement also enabled rapid access for people with these mutations if the labels of the existing medicines were expanded to cover additional age groups and if new Vertex medicines were approved for these populations.

Ludovic Fenaux, Senior Vice President, Vertex International, said, “With this expanded agreement, even more patients in the Republic of Ireland will be among the first in Europe to benefit from the triple combination treatment once the medicine is licensed.”

Triple combination treatment (elexacaftor, tezacaftor and ivacaftor) is not currently licensed for use in the European Union. Vertex submitted a Marketing Authorization Application to the European Medicines Agency on October 31, 2019.

About Vertex

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has four approved medicines in the U.S. and three approved medicines in Europe that treat the underlying cause of cystic fibrosis (CF) — a rare, life-threatening genetic disease — and has several ongoing clinical and research programs in CF. Beyond CF, Vertex has a robust pipeline of investigational small molecule medicines in other serious diseases where it has deep insight into causal human biology, including pain, alpha-1 antitrypsin deficiency, and APOL1-mediated kidney disease. In addition, Vertex has a rapidly expanding pipeline of genetic and cell therapies for diseases such as sickle cell disease, beta thalassemia, Duchenne muscular dystrophy and type 1 diabetes mellitus.

Founded in 1989 in Cambridge, Mass., Vertex's global headquarters is now located in Boston's Innovation District and its international headquarters is in London, UK. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia and Latin America. Vertex is consistently recognized as one of the industry's top places to work, including 10 consecutive years on Science magazine's Top Employers list and top five on the 2019 Best Employers for Diversity list by Forbes.

Special Note Regarding Forward-looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, including, without limitation, the statements by Mr. Fenaux in the second paragraph of this press release and statements regarding the expansion of the existing long-term cystic fibrosis reimbursement agreement and Vertex’s Marketing Authorization Application submission to the European Medicines Agency. While Vertex believes the forward-looking statements contained in this press release are accurate, these forward-looking statements represent the company's beliefs only as of the date of this press release and there are a number of risks and uncertainties that could cause actual events or results to differ materially from those expressed or implied by such forward-looking statements. Those risks and uncertainties include, among other things, that data from the company's development programs may not support registration or further development of its compounds due to safety, efficacy or other reasons, obtaining approval and commercializing elexacaftor, tezacaftor and ivacaftor in Europe, developing additional medicines to treat cystic fibrosis, and other risks listed under Risk Factors in Vertex's annual report and subsequent quarterly reports filed with the Securities and Exchange Commission and available through the company's website at www.vrtx.com . Vertex disclaims any obligation to update the information contained in this press release as new information becomes available.

(VRTX-GEN)

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

HORNBACH Baumarkt Selects Blue Yonder To Accelerate Its Omni-Channel, Customer-Centric Strategy19.9.2024 09:00:00 CEST | Press release

Leading German DIY retailer will leverage Blue Yonder Commerce microservices to provide customers with innovative “order by, get by” promising and order fulfillment optimization to improve customer satisfaction Today, retail offers a wide range of opportunities. Retailers must consistently focus on the needs of their customers if they want to be successful – even in the future. Tech innovation is accelerating. Consumers want to be free to decide whether they want to shop in the store or via smartphone or computer. Optimally, it should all be connected. Retailers are looking to innovate, add new services, and deliver experiences that consumers love, but they often face a costly and expensive fix because their tech stack was not built for modern experiences with efficiency in mind. That’s why, as a pioneer in innovation and one of the leading DIY retailers in Europe, HORNBACH Baumarkt has selected Blue YonderInventory and Commits Services, part of Blue Yonder Order Management solutions.

Murata Unveils the World’s Smallest Multilayer Ceramic Capacitor with the First 006003-inch Size (0.16mm×0.08mm) Device19.9.2024 08:00:00 CEST | Press release

Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has expanded its innovative range of multilayer ceramic capacitors (MLCCs) with yet another groundbreaking addition. Exemplifying Murata’s continual commitment for minimization, it has developed the world’s first 006003-inch size (0.16 mm x 0.08 mm) MLCC. This achievement represents a volume ratio approximately 75% lower than the existing smallest product, the 008004-inch size (0.25×0.125mm). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240918232327/en/ [Murata Manufacturing Co., Ltd.] Murata’s world’s first 006003-inch size (0.16 mm x 0.08 mm) MLCC (Photo: Business Wire) In recent years, as electronic devices become more sophisticated and compact, the number of electronic components installed has increased, while simultaneously the space required for installation has been reduced. As electronic devices continue to advance in intelligence, there has been a c

Wolters Kluwer expert to speak at Europe's inaugural Microsoft Fabric Community Conference19.9.2024 08:00:00 CEST | Press release

Simon Hjortsberg to share expertise on AI-driven data analysis at Stockholmsmässan, Sweden, September 24-27, 2024 Wolters Kluwer Tax & Accounting (TAA), a global leader in professional information, software solutions, and services, today announced that Simon Hjortsberg, the company's Manager of Business Intelligence, will be a keynote speaker at Europe's first-ever Microsoft Fabric Community Conference. The anticipated event will take place from September 24 to 27, 2024, at Stockholmsmässan, in Sweden. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240918799017/en/ Simon Hjortsberg, Manager, Business Intelligence, Wolters Kluwer Tax & Accounting (Photo: Business Wire) On Wednesday, September 25, Simon Hjortsberg will deliver a presentation on “Sharing Experiences with Fabric Copilot.” As an experienced Global Senior Business Intelligence Analyst, Hjortsberg will delve into the ways generative AI features are transforming dat

Dfns Wallet Infrastructure Now Available on Temenos Exchange19.9.2024 07:37:00 CEST | Press release

Dfns offers a Wallets-as-a-Service (WaaS) platform that enables organizations to easily create, integrate, and manage digital assets at scale, delivering enhanced wallet security and efficiency for financial institutions and fintech companies. Dfns, a leading provider of wallets-as-a-service (WaaS) solutions, today announced Dfns Wallet Infrastructure is available on Temenos Exchange, the partner ecosystem of integrated fintech solutions. This partnership makes Dfns the first European digital asset infrastructure provider to integrate with Temenos, joining a select group that includes Wyden, Fireblocks, and Taurus. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240918695901/en/ Dfns Wallet Infrastructure Now Available on Temenos Exchange (Graphic: Business Wire) The Dfns Wallet Infrastructure delivers critical business benefits tailored to the needs of institutional finance and banks. By integrating with Temenos, our solutio

Aizon Launches New AI-powered eBR Light Solution to Enhance Manufacturing Productivity in Collaboration with Euroapi18.9.2024 18:00:00 CEST | Press release

Aizon, an Artificial Intelligence (AI) SaaS provider dedicated to transforming pharmaceutical manufacturing operations, is launching a new product called Aizon Execute, an innovative eBR (Electronic Batch Record) software product, developed in collaboration with Euroapi, a leading global API manufacturer. This collaboration was born out of the need to digitize operations towards more data-driven manufacturing - focusing on the essential user needs while avoiding the heavy lift currently associated with going paperless in manufacturing. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240918037613/en/ Aizon Execute is a modern, user-centric, lightweight product designed to adapt to small-scale productions and highly flexible plants like chemical API CDMOs - and has the potential to become the true backbone of digital transformation journeys. Aizon Execute light eBR is designed to facilitate the rapid transition from paper-based

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye